In the context of RCC, antibodies blocking programmed cell death 1 (PD1), such as nivolumab [52], or blocking its ligand (PD-L1), such as atezolizumab or avelumab, were approved by regulatory agencies (FDA, EMA), together with an antibody interfering with the activity of a different immune checkpoint molecule, CTLA4 (ipilimumab) [53]. Here, CD274 is linked to renal cell carcinoma.